|
3-amino-7,8-dihydroimidazo-(1,5-c)-pyrimidin-5(6H)-one
|
C549309 |
|
|
8-((4-amino-1-methylbutyl)amino)-6-methoxy-4-methyl-5-(3,4-dichlorophenoxy)quinoline
|
C549310 |
|
|
(2S)-p-hydroxyphenethyl 2-bromo-2-methyldodeconate
|
C549311 |
|
|
EVT 201
|
C549312 |
|
|
3-isopropyloxy-6-morpholino-2-phenylphenalen-1-one
|
C549313 |
|
|
Mob4 protein, Drosophila
|
C549314 |
|
|
Premenstrual Syndrome
|
D011293 |
[A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.
] |
|
Prenalterol
|
D011294 |
[A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME.
] |
|
Prenatal Care
|
D011295 |
[Care provided the pregnant woman in order to prevent complications, and decrease the incidence of maternal and prenatal mortality.
] |
|
Prenatal Diagnosis
|
D011296 |
[Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth.
] |
|
Prenatal Exposure Delayed Effects
|
D011297 |
[The consequences of exposing the FETUS in utero to certain factors, such as NUTRITION PHYSIOLOGICAL PHENOMENA; PHYSIOLOGICAL STRESS; DRUGS; RADIATION; and other physical or chemical factors. These consequences are observed later in the offspring after BIRTH.
] |
|
Feprazone
|
D011298 |
[A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)
] |
|
Prenylamine
|
D011299 |
[A drug formerly used in the treatment of angina pectoris but superseded by less hazardous drugs. Prenylamine depletes myocardial catecholamine stores and has some calcium channel blocking activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1406)
] |
|
D-erythro-2-hexenoic acid gamma-lactone
|
C549373 |
|
|
Reamberin
|
C549374 |
|
|
HSD9 protein, human
|
C549375 |
|
|
Xuebijing
|
C549376 |
|
|
Ucn1 protein, mouse
|
C549377 |
|
|
Yaf2 protein, Drosophila
|
C549378 |
|
|
AKL-0707
|
C549379 |
|
